Severe aortic stenosis (narrowing of the aortic valve) affects more than 100,000 people in the United States. If left untreated, about half the people with this condition will die within two years. While the standard treatment option is open-heart valve replacement, many patients are deemed ineligible or too high risk for open-heart surgery.

OhioHealth was the first hospital system in Ohio to offer two, non-surgical options for treating aortic stenosis. Catheter-based procedures like these are the future of heart valve replacement and offer many benefits. In particular, the non-invasive approach allows patients to avoid a large chest incision, which reduces the risk of complications and shortens recovery times. 

Transcatheter Aortic Valve Replacement (TAVR)

For patients deemed inoperable for open-heart surgery, a new, FDA-approved procedure -- transcatheter aortic valve replacement (TAVR) -- is now available as an immediate treatment option at Riverside Methodist. The Edwards SAPIEN Transcatheter Heart Valve is used to replace the diseased native heart valve using a catheter-based procedure.

Transcatheter aortic valve replacement (TAVR) procedures take place in a "hybrid room," which is part operating room and part catheterization lab. Patients are managed by a team consisting of a cardiovascular surgeon, an interventional cardiologist, an anesthesiologist, an echocardiographer, a perfusionist and a staff of nurses and radiology technicians.

 A Second, Innovative Option for High-Risk Patients

The Medtronic CoreValve U.S. Pivotal Trial is the latest non-surgical option for  patients who need aortic valve replacement.

Going in through small incisions in the groin, the shoulder or directly between the ribs, doctors can insert a bioprosthetic valve through a catheter without removing the native valve. 

OhioHealth is among a select group of leading U.S. hospitals participating in the trial to evaluate this minimally invasive alternative to open-heart surgery.